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HIV infection increases a woman’s risk for cervical cancer, and cervical cancer incidence
and mortality rates are higher in countries with high HIV prevalence and limited resources
for screening. Visual inspection with acetic acid (VIA) allows screening and treatment of cer-
vical lesions in a single-visit approach (SVA), but data on its performance in HIV-infected
women are limited. This study’s objective was to examine cervical cancer screening using
VIA/SVA in programs serving HIV-infected women.
Methods
A VIA/SVA program with cryotherapy for VIA-positive lesions was implemented in Côte
d’Ivoire, Guyana, and Tanzania from 2009 to 2012. The effect of HIV status on VIA positivity
and on presence of cryotherapy-eligible lesions was examined using a cross-sectional
study design, with Chi-square tests for comparisons and constructed multivariate logistic
regression models. A P-value of < 0.05 was significant.
Findings
VIA was performed on 34,921 women, 10% (3,580) were VIA positive; 2,508 (85%) eligible
women received cryotherapy during the same visit; only 234 (52%) of those who postponed
returned for treatment; 622 (17%) VIA-positive women had lesions too large to be treated
with cryotherapy and were referred for excisional treatment. In multivariate analysis—con-
trolling for HIV status, location of the screening clinic, facility location, facility type, and coun-
try—compared to HIV-uninfected/unknown women, HIV-infected women had higher odds
of being VIA positive (OR 1.95, 95% CI 1.76, 2.16, P<0.0001) and of having large lesions
requiring referral (OR 1.93, 95% CI 1.49, 2.51, P< 0.0001). Minor treatment complications
occurred in 19 of 3,032 (0.63%) women; none required further intervention.
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Conclusions
This study found that compared to HIV-uninfected/unknown women, HIV-infected women
had nearly twice the odds of being VIA-positive and to require referral for large lesions. SVA
was safe and resulted in significant reductions in loss to follow-up. There is increased need
for excisional treatment in countries with high HIV prevalence.
Introduction
Compared to HIV-negative women, women infected with HIV have higher prevalence rates
and longer persistence of human papillomavirus (HPV) infection, the primary cause of cervical
cancer, and higher rates of cervical dysplasia, the precursor of invasive cervical cancer.[1,2]
Furthermore, cervical cancer incidence and mortality rates are higher in countries with high
HIV prevalence rates and few resources for screening and prevention.[3,4]
Because invasive cervical cancer does not develop until approximately 10–15 years after
initial HPV infection, there is an opportunity to diagnose and treat cervical cancer precursors
and to interrupt progression to cancer.[5] Since the introduction of cervical cytology, mortal-
ity from cervical cancer in developed countries has decreased by more than 70%. The lifetime
risk of cervical cancer can be reduced by approximately 80–90% by screening women every
three to five years.[6] However, in countries with limited resources, implementation of cervi-
cal cytology services is constrained by the inadequate health infrastructure, including a lack
of cytopathologists and cytology technicians to prepare and analyze Pap smears, and the
need for follow-up visits for further evaluation and treatment when Pap smears are abnor-
mal.[7]
Visual inspection of the cervix with acetic acid (VIA) is a low-cost, low-technology
approach to cervical cancer screening that enables identification of precancerous lesions that
can be treated with ablative (e.g., cryotherapy) or excisional (e.g., loop electrosurgical excision
procedure, or LEEP) treatment, potentially in a single-visit approach (SVA). VIA/SVA has
been shown to be a cost-effective, safe, feasible, and acceptable alternative to cytology, with
comparable sensitivity.[8,9]
However, there are limited data on the provision, performance, and integration of cervi-
cal cancer screening using VIA/SVA in programs serving women with HIV infection and
how findings may differ from HIV-uninfected women. This paper reports results from
three country programs that introduced VIA/SVA for cervical cancer screening and preven-




This study reports results from a program evaluation involving three countries (Guyana in
South America, Côte d’Ivoire in West Africa, and Tanzania in East Africa) that implemented a
cervical cancer screening program using VIA/SVA from January 2009 to March 2012 in 24
HIV care and treatment and 23 reproductive and child health clinics (Table 1). Using informa-
tion from first screening appointments, the effect of HIV status on VIA positivity and on pres-
ence of large, cryotherapy-ineligible lesions requiring referral, was examined using a cross-
sectional study design.
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Procedures and Participants
To prepare providers to perform VIA and cryotherapy, all three countries used a standardized
package that consisted of six days of training covering basic information about cervical cancer
and its precursors and included a practicum component and a skills/knowledge assessment.
Providers’ competency was assessed by an objective test of knowledge and by trainers’ observa-
tions of their performance of procedures. The providers were nurses, midwives, midlevel pro-
viders (clinical officers, assistant medical officers, and medex—a nationally recognized cadre of
midlevel-providers in Guyana), and physicians.
Prior to VIA, all women received education and counseling. VIA was performed by applica-
tion of 3–5% acetic acid to the cervix; one minute after application the cervix was examined
with the naked eye using a bright light. With visual inspection techniques, there are three possi-
ble results: negative, positive, or suspicious for cancer, with the last result requiring referral and
further evaluation and management. VIA was considered negative when no acetowhite lesions
were detected; positive when dense, opaque, well-defined acetowhite lesions involving the
squamocolumnar junction were seen; and suspicious for cancer if a friable exophytic mass or
ulcerative lesion was present on initial visualization. Women who were VIA negative were
given a card with their diagnosis and a recommendation to be rescreened in three to five years
if HIV-uninfected and in one year if HIV-infected. Women with a positive VIA result were
offered immediate cryotherapy when all of the following criteria were met: the lesion involved
less than three quadrants of the transformation zone with no extension greater than two milli-
meters into the cervical canal or extension onto the vaginal walls; the entire lesion could be
Table 1. Baseline facility and provider characteristics, by country.
Variables Côte d’Ivoire Guyana Tanzania Total
Service Delivery Period
Start date–end date Oct 2009 –Mar 2012 Jan 2009 –Mar 2012 Apr 2010 –Mar 2012 Jan 2009 –Mar 2012
Number of Project Sites
Total 20 16 11 47
Location of Cervical Cancer Screening Clinic
HIV care and treatment clinic (%) 20 (100%) 4 (25%) 0 (0%) 24 (51%)
Reproductive and child health clinic (%) 0 (0%) 12 (75%) 11 (100%) 23 (49%)
Facility Location
Urban (%) 20 (100%) 6 (38%) 2 (18%) 28 (60%)
Peri-urban (%) 0 (0%) 2 (13%) 2 (9%) 4 (9%)
Rural (%) 0 (0%) 8 (50%) 7 (64%) 15 (32%)
Facility Type
National hospitals (%) 1 (5%) 1 (6%) 0 (0%) 2 (4%)
Regional hospital (%) 4 (20%) 7 (44%) 2 (18%) 13 (28%)
District hospital (%) 9 (45%) 5 (31%) 7 (64%) 21 (45%)
Health center (%) 6 (30%) 3 (19%) 2 (18%) 11 (23%)
Number of people trained
Total 108 43 34 185
Cadre of trained cervical cancer screening providers
Physician/clinical officers, medical officers/medex (%) 52 (48%) 27 (63%) 11 (32%) 90 (49%)
Nurse (%) 12 (11%) 9 (21%) 23 (68%) 44 (24%)
Midwife (%) 44 (41%) 7 (16%) 0 (0%) 51 (27%)
Age of provider (years)
Average (range) 41 (27–55) 40 (25–55) 42 (26–61) 41 (25–61)
doi:10.1371/journal.pone.0139242.t001
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covered by the cryoprobe; the squamocolumnar junction was fully visible; and there was no
suspicion of invasive cancer.
Cryotherapy was done with a double-freeze technique (three-minute freeze, five-minute
thaw, three-minute freeze) without local anesthesia. After screening and/or treatment, women
were given a card with their diagnosis and a recommended follow-up date. Women were
advised on precautions after cryotherapy, including avoiding sexual activity for four weeks dur-
ing healing, and symptoms of possible complications (e.g., bleeding, infection). Condom use
was recommended for all sexual activity. Women were advised to return for clinical follow-up
one year after treatment, for repeat VIA to assess treatment success. Women with lesions that
were not eligible for cryotherapy were referred to a site that offered LEEP; those with lesions
suspicious for invasive cancer were referred for confirmatory diagnosis and definitive treat-
ment. Provider competency was maintained by supervision in the field on at least a quarterly
basis, with direct observation and extended onsite coaching and mentoring.
In this study, VIA/SVA programs targeted but were not limited to HIV-infected women
between the ages of 30 and 50 who self-selected to receive screening. Oral informed consent for
screening was given by all women, and women receiving treatment gave consent again at the
time of the treatment. HIV status was by self-report in Guyana and by record review for Tanza-
nia and Côte d’Ivoire. Patients were considered to have HIV-unknown status if they reported
never receiving HIV testing or results of testing. Provider-initiated HIV testing and counseling
was also integrated into the cervical cancer screening program in Tanzania.[10] Positive HIV
status was confirmed by review of patient cards carried to clinical visits when available.
Patient-level information regarding CD4 count and antiretroviral therapy (ART) was not avail-
able for this analysis. Providers were not blinded to the HIV status of the patient prior to
screening.
Statistical Analysis
For Côte d’Ivoire and Guyana, aggregate data by facility were collected using a monthly sum-
mary form with 10 key binary indicators reflecting outcomes of screening, treatment, and refer-
ral, disaggregated by HIV status and visit type (initial visit, routine screening after negative
result at first screening, and follow-up visit one year after treatment), and entered into Excel.
There were no individual patient identifiers. In Tanzania, patient-level data from individual cli-
ent records were entered into a database. All data were de-identified and all patient records and
information were anonymized and de-identified by data entry personnel prior to sending it to
the authors for analysis. The aggregated data were converted into individual data first and then
the data for the three countries were analyzed separately and then pooled for the analysis. For
this analysis, women who reported HIV negative status and those of unknown status were
grouped together, as they could not be reliably separated due to the aggregation configuration
of the monthly reporting format used in Guyana and Cote d’Ivoire, problems with consistent
availability of HIV testing in Tanzania, and, for those reporting HIV negative results, the vari-
able time interval since testing. Variables were reported as percentages and chi-square tests
were performed. Multivariable logistic regression models were used to examine the relationship
between HIV status and VIA status and between HIV status and larger lesions status of VIA-
positive patients. Variables that were associated with VIA status at a level of significance of
P< 0.2 were included in the multivariable analyses as potential confounders. The statistical
program used was SAS Version 9.3 (SAS Institute, Cary, NC). The overall level of significance
used in this study was P< 0.05.
This program evaluation protocol was reviewed and determined to not qualify as human
subjects research as defined by DHHS regulations 45 CFR 46.102 by the Johns Hopkins
Cervical Cancer Screening and HIV Status in Low Resource Countries
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Bloomberg School of Public Health Institutional Review Board and each country’s Ministry of
Health determined that this was public health practice data and not research so no local institu-
tional review board application was necessary after the MOH approval.
Results
Baseline Characteristics
Baseline characteristics of facilities and providers are presented by country in Table 1. All facili-
ties in Côte d’Ivoire were HIV care and treatment sites, although some women of unknown or
uninfected HIV status were also seen in these sites. In all sites in Tanzania and in 75% of Guy-
ana sites, services were provided in reproductive and child health clinics, and HIV-infected
women in care were referred from a co-located HIV care and treatment clinic. Urban, peri-
urban, and rural sites were well-represented in Tanzania and Guyana; in Côte d’Ivoire, all 20
sites were classified as urban. All but one facility in Guyana were part of the public health sys-
tem. A total of 185 providers were trained in and provided VIA/SVA services; 51% were nurses
or midwives.
Overall Project Results
Fig 1 presents cumulative results of key indicators by country from the beginning of the project
through the end of data collection for this report. A total of 34,921 women received VIA
screening for the first time between January 2009 and March 2012, and VIA-positive rates ran-
ged from 7% to 13% in the three countries (mean 10%). Cases suspicious for invasive cancer
were 2% or less for all cases in Côte d’Ivoire, Guyana, and Tanzania. Across the three countries
an average of 85% (range of 78–92%) of VIA-positive women who were eligible for cryotherapy
received this procedure at the same visit. Among those who postponed treatment, only 52%
(range of 18–55%) returned later for cryotherapy. A total of 622 (17%) of the VIA-positive
women (range of 15–31%) had lesions that were too large to be treated effectively with cryo-
therapy. These women were referred for LEEP, although capacity to perform LEEP was limited
in all three countries during the time covered by this analysis and only 290 (47%) LEEPs were
performed. LEEP was not performed in a single-visit approach in any of the three countries.
Both issues contributed to a high loss-to-follow-up rate in each country (data not shown).
Effect of HIV Status
In each country, HIV-infected women were more likely to be VIA-positive and were more
likely to have large lesions that were not eligible for treatment with cryotherapy (Table 2) than
uninfected/unknown women. In bivariate analysis, variables significantly associated with VIA
positivity included location of the screening, facility type, and country, but not HIV status or
facility location (Table 3). However, with multivariate analysis, adjusted for each of these vari-
ables, found HIV infection to be an independent predictor of VIA positivity. This effect was
modified significantly by the country when compared with women who were HIV-uninfected
or with unknown HIV status (Guyana OR 1.32, 95% CI 1.14, 1.54, P 0.0003; Côte d’Ivoire OR
3.33, 95% CI 2.44, 4.52, P<0.0001; Tanzania OR 2.52, 95% CI 2.09, 3.03, P<0.0001) Overall,
HIV-infected women in all three countries had 1.95 times higher odds of being VIA-positive
than women without HIV or with unknown HIV status (95% CI 1.76, 2.16, P< 0.0001)
(Table 3). In the logistic regression model, women undergoing VIA in Guyana had higher odds
of being VIA-positive as compared to Tanzania (Guyana OR 2.22, 95% CI 1.97, 2.51,
P<0.0001). Being seen in an HIV clinic was associated with lower likelihood of VIA-positivity
(HIV clinic OR 0.75, CI 0.64, 0.89, P.001).
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When examining predictors of large lesions requiring referral among women who were
VIA-positive, bivariate analysis found that HIV status, location of the screening, facility type
and location, and country were all significantly associated with presence of large lesions
(Table 4). However, multivariate logistic regression adjusting for each of these variables found
that independent predictors of large lesion size included HIV status, location of VIA screening
clinic and being screened in a national facility as compared to a regional facility (HIV status
OR 1.93, CI 1.49, 2.51, P<0.0001; HIV clinic OR 3.44, CI 2.19, 5.42, P<0.0001; national facil-
ity OR 2.16, CI 1.57, 2.97, P, 0.0001). HIV status was not associated with increased odds of hav-
ing lesions suspicious for cancer (data not shown).
Of all women who were VIA-positive and had lesions eligible for cryotherapy, 85% were
treated at the same visit; of those who postponed treatment, only 52% returned for cryotherapy
at a later date and there were no differences by HIV status (data not shown).
Complications
Over the course of this study, 19 of 3,032 treated women returned (0.63%) to the health facility
and reported treatment complications after treatment with either cryotherapy or LEEP
Fig 1. Cervical cancer screening and treatment outcomes in three countries.
doi:10.1371/journal.pone.0139242.g001
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Table 2. Comparison of VIA and large lesion results in newwomen screened, by country and HIV status, January 2009 –March 2012.
Screening Result, by Country Total N = 34,921 HIV Positive N = 9,181 HIV negative/ unknown N = 25,740 P-value
Côte d’Ivoire n = 7,538 n = 5,782 n = 1,756
VIA negative 6,969 (92%) 5,268 (91%) 1,701 (97%) < 0.0001
VIA positive 519 (7%) 473 (8%) 46 (3%) < 0.0001
Large lesions 159 (31%) 152 (32%) 7 (15%) 0.0175
Cryotherapy eligible 360 (69%) 321 (68%) 39 (84%) 0.0175
Suspect cancer 50 (.7%) 41 (0.7%) 9 (0.5%) 0.3741
Guyana n = 19,934 n = 1,602 n = 18,332
VIA negative 17,297 (87%) 1,344 (84%) 15,953 (87%) < 0.0001
VIA positive 2,529 (13%) 256 (16%) 2,273 (12%) < 0.0001
Large lesions 381 (15%) 62 (24%) 319 (14%) < 0.0001
Cryotherapy eligible 2,148 (85%) 194 (76%) 1,954 (86%) < 0.0001
Suspect cancer 108 (.5%) 2 (0.1%) 106 (0.6%) 0.0178
Tanzania n = 7,449 n = 1,797 n = 5,652
VIA negative 6,739 (90%) 1,531 (85%) 5,208 (92%) < 0.0001
VIA positive 532 (7%) 237 (13%) 295 (5%) < 0.0001
Large lesions 82 (15%) 51 (22%) 31 (11%) 0.0005
Cryotherapy eligible 450 (85%) 186 (78%) 264 (89%) 0.0005
Suspect cancer 178 (2%) 29 (1.6%) 149 (2.6%) 0.0134
doi:10.1371/journal.pone.0139242.t002
Table 3. Bivariate andmultivariate logistic regression model of the odds of screening VIA positive, by HIV status and facility characteristics, all
countries combined.*
Variables VIA Positive (n = 3,580) (%) VIA Negative (n = 31,005) (%) P OR 95% CI P
HIV Status
HIV Positive 27.0 26.3 .035 1.95 1.76, 2.16 <0.0001
HIV Negative/Unknown 73.0 73.7 (r)
Location of Cervical Cancer Screening Clinic
HIV care and treatment clinic 27.9 33.6 <0.0001 0.75 0.64, 0.89 .001
Reproductive and child health clinic 72.1 66.4 (r)
Facility Location
Urban 69.8 69.1 0.12 1 - -
Per-urban 6.8 6.2 1.04 0.88, 1.24 0.63
Rural 23.4 24.7 0.99 0.86, 1.15 0.94
Facility Type
National Hospital 35.0 30.7 <0.0001 .92 0.83, 1.02 0.12
Regional Hospital 20.6 18.6 (r)
District Hospital 22.6 27.0 0.93 0.83, 1.03 0.17
Health Center 21.8 23.7 1.03 0.89, 1.20 0.69
Country
Côte d’Ivoire 14.5 22.5 <0.0001 0.87 0.71, 1.07 0.18
Guyana 70.6 55.8 2.22 1.97, 2.51 <0.0001
Tanzania (r) 14.9 21.7 (r)
(r) Reference category
* The total number of women included in this analysis is lower than the total number of women screened due to missing variables for some women, who
were excluded from analysis.
doi:10.1371/journal.pone.0139242.t003
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(reporting in the case of a complication did not distinguish the type of procedure). All but one
were HIV-uninfected women, and all cases were considered minor, not requiring referral or
ongoing care (data not shown).
Discussion
In this analysis from three countries with high HIV prevalence, HIV status was an independent
predictor of VIA positivity, consistent with an increased prevalence of precancerous cervical
lesions in the setting of HIV. Furthermore, women known to be HIV positive required referral
for large lesions more frequently than women who were HIV uninfected/unknown. Overall,
receiving immediate treatment in a single visit resulted in a significant reduction in loss to fol-
low-up, compared to deferring treatment until a subsequent visit. There was no evidence of sig-
nificant safety concerns with this approach in a low-resource setting or among HIV-infected
women.
More than 85% of cervical cancer cases and deaths occur in developing countries, which
have only 5% of the world’s cancer resources.3 Cervical cancer is the second most common
cancer among women in the developing world and the most common cause of cancer deaths.
[11] In the three countries in this study, cervical cancer rates are high. In Côte d’Ivoire the inci-
dence of cervical cancer is 21.7/100,000 women and the mortality rate from cervical cancer is
14.6/100,000 women. Incidence and mortality rates are even higher in Guyana (46.9/100,000
and 21.9/100,000, respectively) and Tanzania (54.0/100,000 and 32.4/100,000, respectively). In
contrast, in North America, where cervical cancer screening is routine, the cervical cancer inci-
dence and mortality rates are only 6.6/100,000 and 2.7/100,000, respectively.[12]
Table 4. Bivariate andmultivariate logistic regression model of the odds of having a large lesion diagnosed at the first VIA screening, by HIV sta-
tus and facility characteristics, all countries combined.
Variables Small Lesion (n = 2,958) (%) Large Lesion (n = 622) (%) P OR 95% CI P
HIV Status
HIV Positive 42.6 23.7 <0.0001 1.93 1.49, 2.51 <0.0001
HIV Negative/Unknown 57.4 76.3 (r)
Location of Cervical Cancer Screening Clinic
HIV care and treatment clinic 43.8 24.6 <0.0001 3.44 2.19, 5.42 <0.0001
Reproductive and child health clinic 56.2 75.4 (r)
Facility Location
Urban 78.3 68.1 <0.0001 (r)
Peri-urban 4.8 7.1 1.29 0.80, 2.07 0.57
Rural 16.9 24.8 1.30 0.90, 1.89 0.44
Facility Type
National Hospital 35.9 34.8 <0.0001 2.16 1.57, 2.97 <0.0001
Regional Hospital 14.2 22.0 (r)
District Hospital 21.6 22.8 0.93 0.65, 1.33 0.69
Health Center 28.3 20.4 0.84 0.57, 1.25 0.39
Country
Côte d’Ivoire 25.6 12.2 <0.0001 0.56 0.35, 0.93 0.03
Guyana 61.2 72.6 0.72 0.51, 1.02 0.06
Tanzania 13.2 15.2 (r)
(r) Reference category
doi:10.1371/journal.pone.0139242.t004
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Case-control and cross-sectional studies in various African countries, including Côte
d’Ivoire and Tanzania, have found an association between HIV infection and invasive cervical
cancer.[13,14] The strength of the association has varied in these studies, possibly reflecting the
competing risk of dying from other HIV-related conditions or other illnesses.[12,15] HIV prev-
alence in Côte d’Ivoire (3%), Guyana (1.1%), and Tanzania (5.8%) is significantly higher than
the overall HIV prevalence in North America (0.5%).[16] Unlike other typical opportunistic
infections, the burden of HPV or HPV-related complications has not been shown to decline
with effective ART;[17] this could mean that increased numbers of women will be at risk for
cervical cancer as HIV treatment programs become more accessible and successful and HIV-
positive women live longer. A recent mathematical model projected that, compared with no
ART and no screening, the lifetime cumulative risk of dying from cervical cancer approxi-
mately doubled with ART and no screening. However, even one screening had the potential to
reduce cervical cancer mortality.[18] These findings have important implications for lower-
resource countries, where an increasing number of HIV-infected women are currently access-
ing HIV care and treatment.
Prevention of cervical cancer by identification and treatment of cervical cancer precursors is
central to reducing the disease burden, because treatment resources for invasive diseases are
scarce. In 2002, the survival rate for invasive cervical cancer was 21% in sub-Saharan Africa,
likely related to late presentation and lack of effective treatment resources, including surgical
expertise and radiotherapy.[19,20] However, cervical cytology, which has revolutionized cervi-
cal cancer prevention in developed countries, is not feasible for most countries with limited
resources. Furthermore, many women in these settings reside at some distance from health
centers and have little access to transportation. This is coupled with a lack of effective recall
mechanisms for women with abnormal results.[7] In sub-Saharan Africa, loss-to-follow-up
rates of 60–80% have been reported among those with cytologic abnormalities.[21]
Recent studies have focused on service delivery models using alternatives to cytology for cer-
vical cancer screening in order to improve access to safe and effective treatment, minimize loss
to treatment follow-up, and prioritize use of specialized care. VIA has been shown to be effec-
tive, safe, feasible, and acceptable in multiple studies.[9,22,23] It is inexpensive, can be task-
shifted to lower-level health workers,[24] and allows screening and treatment in a single visit
for those women that are eligible.
In a cluster randomized trial in India in which more than 31,000 women were followed for
seven years, VIA with same-visit cryotherapy for positive results was associated with a 24%
reduction in the incidence of stage 2 or higher cervical cancer and a 35% reduction in cervical
cancer mortality.[9] A recent review of published studies of VIA accuracy, with histology as the
standard and cervical intraepithelial neoplasia 2 (CIN 2 or high-grade cervical dysplasia) or
higher as the outcome measure, found sensitivity to be 79–82%, specificity to be 91–92%, and
positive predictive value to be 9–10%.[25] The World Health Organization (WHO) recently
reported results from a cervical cancer screening demonstration project with VIA and SVA
with cryotherapy in six African countries from 2005−2009. More than 19,000 women were
screened; 10.1% were VIA positive and of these 87.7% were eligible for cryotherapy. The SVA
enabled 39.1% to be screened and treated on the same day.[26]
Data on the accuracy of VIA in the setting of HIV infection are more limited. Studies com-
paring VIA to cytology, with biopsy-documented CIN 2 or higher as the standard, found that
VIA equaled or outperformed cytology. In a research study of 1,202 HIV-infected women in
South Africa, sensitivity for detection of CIN 2 or higher was the highest for HPV testing
(92%) with 76% for both cytology and for VIA (with physician interpretation); specificity was
lowest for HPV testing (51%) and highest for cytology (83%), with VIA intermediate at 68%.
When the results of two tests were combined as either test positive, the HPV/VIA combination
Cervical Cancer Screening and HIV Status in Low Resource Countries
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achieved the highest sensitivity at 95.6%, while the cytology/VIA combination had the highest
specificity at 60.4%.[27] Among 1,128 HIV-infected women screened in India, sensitivity and
specificity for VIA was 83.6% and 88.8%, respectively, as compared to 63.3% and 94.5% for
cytology, respectively.[28]
Reports from Kenya, Botswana, Zambia, and Côte d’Ivoire demonstrate that integration of
VIA into routine HIV care and in settings with high HIV prevalence is feasible and acceptable
[29,30,31,32]. The program in Zambia had the largest number of patients and longest experi-
ence, screening 56,247 women over five years, approximately 15,000 of whom were HIV-
infected, and demonstrating the successful incorporation of VIA screening and SVA through
an HIV-care platform. The study showed that with increasing experience, providers performed
more procedures accurately; rates of VIA positivity fell over time regardless of HIV status. [29]
In a screen and treat program in Western Kenya, of 1,331 HIV-infected and HIV-uninfected
women who were VIA positive, the overall loss to treatment follow up was 31.5%; rates
increased as invasiveness of treatment increased.[33] In one study in North American, the loss
to treatment follow-up rate from abnormal Pap smear results was 26%,[34] demonstrating the
value of SVA, which is not available with cytology.
A randomized clinical trial of VIA and HPV testing, with cryotherapy treatment for positive
results, was performed among more than 6,500 women in South Africa, of whom 956 were
HIV-infected. Thirty-six months after screening, women were followed up with colposcopy
and biopsy to determine the presence of CIN 2. VIA reduced the likelihood of CIN 2 at follow-
up, but to a lesser degree than HPV testing, and statistical significance was attained only in
HIV-infected women (RR 0.51 [95% CI; 0.29–0.89]).[35]
The evaluation reported in this study has several limitations. HIV testing was only per-
formed in the context of the cervical cancer screening program in Tanzania for those women
who reported HIV status unknown or had a negative result older than six months and at times
test kits were not available; we were therefore largely dependent on self-report of HIV status,
especially in Guyana, where the majority of screening was performed in reproductive and child
health clinics. However, false-positive reports of HIV infection are likely uncommon, given
stigma and discrimination associated with HIV status. It is likely that some of the women in
the HIV-uninfected/unknown comparison group were in fact HIV-infected. If this is true, it is
probable that misclassification resulted in an underestimation of the differences between the
HIV-infected and the HIV-uninfected/unknown groups. Sensitivity analysis performed on
Tanzanian data treating those with unknown HIV status as either HIV-positive or HIV-nega-
tive did not change findings (data not shown). Because this analysis was conducted within
existing private and public sector clinics and in a “real world setting” and not in the context of
a research study, there may be possible sources of bias. Providers were not blinded to the HIV
status of the women they screened, possibly leading to over-call of VIA positivity in HIV-
infected women. The finding that women in Guyana had higher odds of being VIA-positive
may reflect the inherent subjectivity of VIA or other individual or country specific factors not
captured in this evaluation. Additional potentially confounding variables such as age, CD4
count, and ART status were not available for this analysis. Although VIA-positive findings
were not confirmed by biopsy in this program evaluation, studies noted above have validated
the performance characteristics of VIA.
The findings of this analysis from a real-world setting are consistent with results of research
studies in well-resourced settings using cytology as a screening technique and studies from low
resource setting using VIA as the primary screen, which have found that HIV-infected women
have higher rates of cervical precancerous abnormalities compared to HIV-uninfected women.
The strengths of this evaluation include the confirmation that HIV-infected women are more
likely to have lesions involving a larger area of the cervix, requiring more extensive treatment,
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and establishment of SVA as a strategy to reduce loss to treatment follow-up for cryotherapy-
eligible women. The large number of women screened and the consistency of primary findings
across countries in both South America andWest and East Africa, despite limitations in avail-
able data, as well as the inclusion of varied sites and different clinical settings, enhance the
validity of our findings.
Conclusions
An overarching goal of the newWHO global health sector strategy on HIV/AIDS is to achieve
universal access to comprehensive HIV prevention, treatment, and care, including strengthen-
ing linkages between HIV and other related health programs, such as cervical cancer screening
and care.[36] The findings of this study have significant implications for the integration of cer-
vical cancer screening into HIV care. They suggest an increased need for referral and/or incor-
poration of excisional treatment, rather than cryotherapy alone, requiring more training and
greater resources. Further analyses that include ART status and CD4 counts are important to
further inform screening and treatment protocols and guidelines on appropriate screening
strategies and intervals. Further study is needed to assess whether screening earlier in the
course of HIV, when there is less immunosuppression, might also be associated with smaller
and more treatable lesions, or whether ART and associated immune reconstitution would
make a difference in rates of VIA positivity and lesion size. It is also critical to consider models
of care to integrate cervical cancer screening into HIV care settings to enhance test perfor-
mance, feasibility, and scale-up.
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